Do you want to read an article? Please log in or register.
Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma - findings from the PRACTICAL study, a randomised clinical trial
Asthma
RECOMMENDED
Related content
Asthma
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med.
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators
doi: 10.1016/
RECOMMENDED
Asthma
What matters most to patients when choosing treatment for mild-moderate asthma? Results from a discrete choice experiment
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Thorax.
Baggott C, Hansen P, Hancox RJ, Hardy JK, Sparks J, Holliday M, Weatherall M, Beasley R, Reddel HK, Fingleton J, PRACTICAL discrete choice experiment study team
doi: 10.1136/thoraxjnl-2019-214343.
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>
doi: 10.1016/
RECOMMENDED
Asthma
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial
Lancet.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R, PRACTICAL study team.
doi: 10.1016/S0140-6736(19)31948-8.
COMMENTED
Asthma
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Mansur AH, Fowler SJ, Niven RM, Howarth PH, Lordan JL, Menzies-Gow A, Harrison TW, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, investigators for the MRC Refractory Asthma Stratification Programme.
doi: 10.1016/S2213-2600(20)30397-0.
Asthma
Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma - a pre-specified analysis from the PRACTICAL study, a randomised controlled trial
Eur Respir J.
Baggott C, Hardy J, Sparks J, Holliday M, Hall D, Vohlidkova A, Hancox R, Weatherall M, Fingleton J, Beasley R, PRACTICAL study team.
doi: 10.1183/13993003.00170-2020.
Asthma
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
J Asthma.
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY
doi: 10.1080/02770903.
RECOMMENDED
Further Publications
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE
doi: 10.1016/S2213-2600(21)00226-5
Asthma
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study
Lancet Respir Med.
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, Reddel HK
doi: 10.1016/S2213-2600(20)30416-1.